40+ page practical reference guide for auditing Medicare rates, spotting underpayments, and turning fee schedule data into operational decisions.
Looking up rates? Get the full 2026 Medicare Fee Schedule handbook.
Current CMS pricing and breakdown for Onc uc dna mthyltn&mut 6bmrk.
A national base rate is not currently published.
Don't rely on national estimates. Use our free Master Search Tool to find the exact rate for your specific Zip Code or browse 18,000+ other billing codes.
Oncology (urothelial carcinoma), dna methylation and mutation analysis of 6 biomarkers (twist1, otx1, onecut2, fgfr3, hras, tert promoter region), methylation-specific pcr and targeted next-generation sequencing, urine, algorithm reported as a probability index for bladder cancer and upper tract urothelial carcinoma
CPT code 0613U (Oncology (urothelial carcinoma), dna methylation and mutation analysis of 6 biomarkers (twist1, otx1, onecut2, fgfr3, hras, tert promoter region), methylation-specific pcr and targeted next-generation sequencing, urine, algorithm reported as a probability index for bladder cancer and upper tract urothelial carcinoma) does not currently have a published national facility or non-facility reimbursement rate in 2026.
0613U is a CPT code in the category “Clinical Laboratory Test.” Medicare does not publish a single national payment amount for this code in 2026 (No National Rate). A national base rate is not currently published.
To estimate a local payment amount when available, use MedFeeSchedule's Medicare Physician Fee Schedule Lookup Tool on the homepage and confirm final pricing guidance through CMS or your local Medicare Administrative Contractor (MAC).
| Component | Office (Non-Fac) | Facility (Hosp) |
|---|---|---|
| Work RVU | ||
| Practice Expense (PE) | ||
| Malpractice (MP) | ||
| Total RVUs | 0.00 | 0.00 |
Compare a payment against the Medicare benchmark for this code.
Medicare rates are used as a benchmark only. Actual payer contracts, modifiers, place of service, units, and billing rules may affect reimbursement. This tool is for educational and operational review purposes, not legal or billing advice.
Facility vs. non-facility pricing most commonly applies to physician services paid under the RVU-based Physician Fee Schedule. For 0613U (Clinical Laboratory Test), the payment methodology may not include both facility and non-facility rates.
Medicare reimbursement is determined by RVUs, geographic adjustments, and the annual conversion factor.
Medicare does not publish a single national reimbursement rate for 0613U in 2026 (No National Rate). Use MedFeeSchedule's Medicare Physician Fee Schedule Lookup Tool to explore locality-adjusted estimates when applicable.
Oncology (urothelial carcinoma), dna methylation and mutation analysis of 6 biomarkers (twist1, otx1, onecut2, fgfr3, hras, tert promoter region), methylation-specific pcr and targeted next-generation sequencing, urine, algorithm reported as a probability index for bladder cancer and upper tract urothelial carcinoma
Facility vs. non-facility differences usually apply to RVU-based physician services. 0613U may not use both facility and non-facility pricing depending on its payment methodology.
Use MedFeeSchedule's Medicare Physician Fee Schedule Lookup Tool on the homepage to estimate your locality-adjusted reimbursement. Medicare payment can vary based on geographic adjustments (GPCI), place of service, and claim specifics.
Coverage depends on medical necessity, setting, and Medicare policy. Some codes may be bundled, contractor-priced, or restricted. Verify final coverage guidance through CMS or your local MAC when applicable.